ahlam1399
07-20-2015, 06:25 PM
Bristol-Myers? Opdivo found effective in kidney cancer
(Reuters) - Bristol-Myers Squibb Co said a late-stage trial of its drug, Opdivo, was stopped early after the immu**therapy was found to be effective in patients with the most common form of kidney cancer.
http://rc.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/rc/1/rc.img (http://rc.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/rc/1/rc.htm)
http://rc.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/rc/2/rc.img (http://rc.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/rc/2/rc.htm)
http://rc.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/rc/3/rc.img (http://rc.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/rc/3/rc.htm)
http://da.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/a2.img (http://da.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/a2.htm)
http://adchoice.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/ach.img (http://adchoice.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/ach.htm)http://pi.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/a2t.imghttp://pi2.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/a2t2.imghttp://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/48460f32/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=mqZ1WZeaGvY:VOAT_eHvqpI:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=mqZ1WZeaGvY:VOAT_eHvqpI:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=mqZ1WZeaGvY:VOAT_eHvqpI:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=mqZ1WZeaGvY:VOAT_eHvqpI:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=mqZ1WZeaGvY:VOAT_eHvqpI:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/mqZ1WZeaGvY
(Reuters) - Bristol-Myers Squibb Co said a late-stage trial of its drug, Opdivo, was stopped early after the immu**therapy was found to be effective in patients with the most common form of kidney cancer.
http://rc.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/rc/1/rc.img (http://rc.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/rc/1/rc.htm)
http://rc.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/rc/2/rc.img (http://rc.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/rc/2/rc.htm)
http://rc.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/rc/3/rc.img (http://rc.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/rc/3/rc.htm)
http://da.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/a2.img (http://da.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/a2.htm)
http://adchoice.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/ach.img (http://adchoice.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/ach.htm)http://pi.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/a2t.imghttp://pi2.feedsportal.com/r/234565843948/u/49/f/654207/c/35217/s/48460f32/sc/14/a2t2.imghttp://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/48460f32/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=mqZ1WZeaGvY:VOAT_eHvqpI:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=mqZ1WZeaGvY:VOAT_eHvqpI:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=mqZ1WZeaGvY:VOAT_eHvqpI:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=mqZ1WZeaGvY:VOAT_eHvqpI:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=mqZ1WZeaGvY:VOAT_eHvqpI:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/mqZ1WZeaGvY